Johns Hopkins HIV Guide
Rilpivirine
INDICATIONS
FDA
FDA
Rilpivirine in combination with other ARVs is indicated for the treatment of HIV-1 infection in ART-naïve patients with HIV-1 RNA < 100,000 copies/mL.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: April 8, 2019
Citation
Smith, Janessa M, and Paul Pham. "Rilpivirine." Johns Hopkins HIV Guide, 2019. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545229/all/Rilpivirine.
Smith JM, Pham P. Rilpivirine. Johns Hopkins HIV Guide. 2019. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545229/all/Rilpivirine. Accessed June 2, 2023.
Smith, J. M., & Pham, P. (2019). Rilpivirine. In Johns Hopkins HIV Guide https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545229/all/Rilpivirine
Smith JM, Pham P. Rilpivirine [Internet]. In: Johns Hopkins HIV Guide. ; 2019. [cited 2023 June 02]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545229/all/Rilpivirine.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Rilpivirine
ID - 545229
A1 - Smith,Janessa, PharmD, BCPS
AU - Pham,Paul,Pharm.D.
Y1 - 2019/04/08/
BT - Johns Hopkins HIV Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545229/all/Rilpivirine
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
